Rxcurve
HCPCS J2428 · per 1 MG

Inj, erzofri, 1 mg

Products billed under this code include Erzofri.

Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J2428

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Erzofri Luye Pharma USA Ltd 72526-0105-11 39 $607.893
Erzofri Luye Pharma USA Ltd 72526-0106-11 78 $1,215.786
Erzofri Luye Pharma USA Ltd 72526-0107-11 117 $1,823.679
Erzofri Luye Pharma USA Ltd 72526-0108-11 156 $2,431.572
Erzofri Luye Pharma USA Ltd 72526-0109-11 234 $3,647.358
Erzofri Luye Pharma USA Ltd 72526-0110-11 351 $5,471.037

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $15.587 −$0.286 1 MG Inj, erzofri, 1 mg v1, posted September 17, 2026
3Q26 $15.873 +$1.382 1 MG Inj, erzofri, 1 mg v1, posted September 15, 2026
2Q26 $14.491 −$0.812 1 MG Inj, erzofri, 1 mg v1, posted September 15, 2026
1Q26 $15.303 −$1.461 1 MG Inj, erzofri, 1 mg v1, posted September 15, 2026
4Q25 $16.764 – 1 MG Inj, erzofri, 1 mg v1, posted September 8, 2026

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files